Company Profile
JNJ insider trades (13 months) →Today's multi-factor rank: 43 of 466 · see the ranking
Market and Valuation
Price & Market
52-Week Range
Volume
Valuation Multiples
Dividends
Valuation Context
P/E vs sector (indicative)
Loading historical OHLCV database...
| Date | Open | High | Low | Close | Volume |
|---|
Financial Statements TTM (Trailing 12 Months)
Income Statement
Margins
Per Share
Balance Sheet & Liquidity
Cash Flows
Profitability
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
Growth and Margins
Per Share
Cash Flows (TTM)
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
| Quarter | Period | Actual EPS | Estimated EPS | Difference | Surprise % | Currency |
|---|
Ownership Structure
Ownership Distribution
Shares & Short Interest
Governance Score (1=Best, 10=Worst)
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
| Organization | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
| Fund | Report Date | % Shares | No. Shares | Value (USD) | Change % |
|---|
Recent Insider Trades
| Executive / Insider | Title | Date | Action | Shares |
|---|
Options Chain
CALLS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
PUTS
| Strike | Last | Bid | Ask | Vol. | O.I. | IV |
|---|
Sentiment Metrics
Expected move
Johnson & Johnson (JNJ) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
| Type | Date | Official link |
|---|---|---|
| N-PX | 2026-08-11 | View filing ↗ |
| 8-K | 2026-08-04 | View filing ↗ |
| 8-K | 2026-07-29 | View filing ↗ |
| 8-K | 2026-07-28 | View filing ↗ |
| 10-Q | 2026-07-23 | View filing ↗ |
| 8-K | 2026-07-15 | View filing ↗ |
| 11-K | 2026-06-25 | View filing ↗ |
| SD | 2026-05-27 | View filing ↗ |
| 8-K | 2026-04-28 | View filing ↗ |
| 10-Q | 2026-04-22 | View filing ↗ |
Company and Executive Profile
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
General Information
Key Executives
| Name | Title | Age | Total pay |
|---|---|---|---|
| Mr. Joaquin Duato | CEO & Chairman | 62 | 6.50M |
| Mr. Joseph James Wolk CPA | Executive VP & CFO | 58 | 3.22M |
| Dr. John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine and R&D | 67 | 3.17M |
| Mr. Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | 55 | 2.54M |
| Mr. Robert J. Decker Jr. | Controller & Chief Accounting Officer | 52 | - |
| Mr. James Swanson | Executive VP & Chief Information Officer | 59 | - |
| Mr. Ryan Koors | Vice President of Investor Relations | - | - |
| Mr. Dirk Brinckman | Chief Compliance Officer | - | - |
You have seen the engine room
Few finance sites let you get this far, and none we know of also shows you where its knowledge ends. If this way of working convinces you, the thing almost nobody catches in time can reach you by email: the big insider buys — executives and major shareholders putting in their own money — the same day they report them to the SEC, with the Form 4 linked. It takes three steps and none of them costs anything: create the account, confirm the email we send you, then switch the alert on in your profile (the icon at the top right). It starts off and it goes off again with the same click. Along the way all three are saved: your simulator portfolios, your personal portfolio and your Academy progress, synced across devices.